Publication
Targeting addiction to HMGB2-driven transcriptional programs in pancreatic cancer.
Adi Danieli-Mackay, Ioanna Papadionysiou, Markos Tsitsianopoulos, Fabio Bennet Gätje, Henrik Spahn, Christian Schmidt, Lukas Klein, Shyam Ramasamy, Nadine Übelmesser, Jennifer Appelhans, Olga Dschun, Emre Taylan Duman, Fabian Ludewig, Sebastian Schimkowiak, Matthias Dobbelstein, Gabriela Salinas, Philipp Ströbel, A Marieke Oudelaar, Tiago De Oliveira, Shiv Kishor Singh, Gernot Längst, Lena-Christin Conradi, Argyris Papantonis
- Source
- PubMed
- Retrieved
- Sep 28, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20260928-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Pancreatic cancer remains at a stagnant 5-year survival of <13%, attributed to the high heterogeneity and plasticity of these tumors. To circumvent this, we focus on the abundant nuclear protein high mobility group-box protein 2 (HMGB2). HMGB2 depletion is key for establishing replicative…
Read on PubMedLinked entities
Linked entities (1)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Candidate 1
- cancerMalignant Pancreatic Neoplasmdictionary0.60
Curated evidence
Evidence citing this paper (0)
Data not yet available